Celltrion highlights biosimilar savings on 10th anniversary in Europe

South Korea's Celltrion Healthcare (Kosdaq: 068270) has launched a campaign to celebrate a decade of continuous biosimilar innovation in Europe.

The campaign coincides with 10 years since the world’s first monoclonal antibody biosimilar infliximab, Remsima, received regulatory approval from the European Medicines Agency, as a copy of Janssen’s biologic Remicade.

Celltrion has stressed how, during the decade since, thousands of patients in Europe and globally have benefitted from biosimilars, bringing both patient health and economic benefits. This has been particularly so in immune-mediated inflammatory diseases such as inflammatory bowel disease and rheumatoid arthritis.